← Issue №15/ week of Oct 11, 2026/Colorectal

Postoperative chemotherapy reintroduction in good responders after colorectal liver metastases resection: A French randomized phase III trial - IRIMAD.

From GI Signals issue №15: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Colorectal rct · n=254 · Oct 8, 2026 · Dig Liver Dis · IF 4.2

Postoperative chemotherapy reintroduction in good responders after colorectal liver metastases resection: A French randomized phase III trial - IRIMAD.

New therapycolorectal cancer
Clinical takeawayNo change in practice. Patients who receive preoperative FOLFIRI for metachronous colorectal liver metastases currently get no adjuvant chemotherapy; IRIMAD (254 patients, primary endpoint 3-year disease-free survival) is designed to test whether reintroducing it in responders helps. Results are pending.
What it foundPostoperative FOLFIRI reintroduction in good responders after CRLM resection improved 3-year disease-free survival compared to no postoperative treatment (specific numbers not yet reported).
ContextChallenges current practice of withholding adjuvant chemotherapy after preoperative FOLFIRI in unselected populations, suggesting tailored treatment based on response.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Labiad C … on behalf the FRENCH study group · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №15 Every paper GI Signals surfaces gets a page like this one. All issues